In this edition of The Motley Fool's Market Checkup, health-care analysts David Williamson and Max Macaluso discuss the treatment of high cholesterol. From the impact of generic versions of Pfizer's Lipitor to the most exciting experimental drugs in late-stage clinical trials, cholesterol continues to be an area of focus for pharmaceutical companies and investors.
You're reading a free article with opinions that may differ from The Motley Fool's Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More
Market Checkup: High Cholesterol
Our weekly healthcare show "Market Checkup" takes a look at the major pharmaceutical players in the high cholesterol space.
David Williamson owns shares of Pfizer and Amarin plc (ADR). Max Macaluso, Ph.D. has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Stocks Mentioned












*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.
Related Articles





Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.